Home » Edwards Lifesciences to Begin Clinical Trial of Transcatheter Valve
Edwards Lifesciences to Begin Clinical Trial of Transcatheter Valve
Edwards Lifesciences has received conditional approval from the FDA for the first cohort of a trial to study the company’s Sapien XT transcatheter heart valve. The first cohort will study up to 450 patients with severe, symptomatic aortic stenosis. The valve is already CE-Marked and is commercially available in Europe.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May